Metallothionein-1 is associated with osteoarthritis disease activity and suppresses proinflammatory cytokines production in synovial cells.

CONCLUSION: The data had shown that the MT-1 was up-regulated in EIOA patients and positively correlated with the disease activity. The recombinant MT-1 could suppress the expression of pro-inflammatory cytokines in both PBMCs and synovial cells from EIOA patients. Therefore, the MT-1 might become a novel therapeutic target for OA treatment.
PMID: 31465913 [PubMed - as supplied by publisher]

Source: International Immunopharmacology - August 25, 2019 Category: Allergy & Immunology Authors: Wang C, Gong Z, Hu S, Zhang G Tags: Int Immunopharmacol Source Type: research